Latest Press Releases

Statement on COVID-19

As we continue to monitor COVID-19 developments, at Neurocrine Biosciences we are committed to the safety, health and well-being of our patients, customers and employees. To healthcare providers and their patients with tardive dyskinesia or Parkinson’s disease, we do not anticipate any disruption in our ability to supply INGREZZA® (valbenazine) or ONGENTYS® (opicapone). Be assured, we remain focused on our mission to discover, develop and deliver important medicines to treat patients with neurological, endocrine, and psychiatric disorders.


Latest SEC Filings

Filing Date Form Description Filing Group View
10/06/21 4

Statement of changes in beneficial ownership of securities

3,4,5
10/06/21 4

Statement of changes in beneficial ownership of securities

3,4,5
10/06/21 4

Statement of changes in beneficial ownership of securities

3,4,5
View All

Shareholder Contacts

Investor Relations Contact

  • Todd Tushla

    Investor Relations, Neurocrine Biosciences

  • 12780 El Camino Real

    San Diego, CA 92130

  • Phone

    858-617-7600

  • E-mail

    ir@neurocrine.com

Information Request

Maecenas feugiat lorem vel est imperdiet, quis hendrerit sapien pretium. Fusce maximus ex sapien, sit amet vulputate.

Request Now

Press Releases

Statement on COVID-19

As we continue to monitor COVID-19 developments, at Neurocrine Biosciences we are committed to the safety, health and well-being of our patients, customers and employees. To healthcare providers and their patients with tardive dyskinesia or Parkinson’s disease, we do not anticipate any disruption in our ability to supply INGREZZA® (valbenazine) or ONGENTYS® (opicapone). Be assured, we remain focused on our mission to discover, develop and deliver important medicines to treat patients with neurological, endocrine, and psychiatric disorders.

Keyword Search
Fri September 10, 2021

– Long-term Data from KINECT 4 Study Found that Long-Term Tardive Dyskinesia (TD) Symptom Reductions were Achieved with Once-Daily INGREZZA – New Pooled Analysis of Two Phase 3 Studies Found Treatment with ONGENTYS as an Add-On to Levodopa/Carbidopa Decreased the Frequency of Nighttime Awakenings

Fri September 10, 2021

– Long-term Data from KINECT 4 Study Found that Long-Term Tardive Dyskinesia (TD) Symptom Reductions were Achieved with Once-Daily INGREZZA – New Pooled Analysis of Two Phase 3 Studies Found Treatment with ONGENTYS as an Add-On to Levodopa/Carbidopa Decreased the Frequency of Nighttime Awakenings

Page 1 of 5

Stock Quote

NBIX (Common Stock)
$103.94
  • Price
    $103.94
    Change
    +0.9
  • Volume
    $103.94
    Change
    +0.9
  • Intraday High
    $103.94
    Change
    +0.9
  • Intraday Low
    $103.94
    Change
    +0.9
  • Today’s Open
    $103.94
    Change
    +0.9
  • Previous Close
    $103.94
    Change
    +0.9
10/08/21 2:18 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed

Image

Historical Quote Lookup

Week Of October 4, 2021

Date Requested Closing Price Volume Open Price Day High Day Low
October 4, 2021 $100.80 587,520 $101.73 $102.80 $100.49
October 4, 2021 $100.80 587,520 $101.73 $102.80 $100.49
October 4, 2021 $100.80 587,520 $101.73 $102.80 $100.49

SEC Filings

SEC Filing Keyword Search
Filing Date Form Description Filing Group View
10/06/21 4

Statement of changes in beneficial ownership of securities

3,4,5
10/06/21 4

Statement of changes in beneficial ownership of securities

3,4,5
10/06/21 4

Statement of changes in beneficial ownership of securities

3,4,5

Partners & Collaborators

Strategic Alliances

  • ABBVIE

    In June 2010, Neurocrine Biosciences entered into an exclusive worldwide collaboration with AbbVie (formerly Abbott) to develop and commercialize elagolix for women’s health. Under the terms of the agreement, AbbVie is responsible for future development and commercialization.

    In 2018, AbbVie received U.S. FDA approval for ORILISSA® (elagolix) to treat pain associated with endometriosis. In 2020, AbbVie received U.S. FDA approval for ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) to manage heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Under the collaboration, elagolix is also being investigated for the treatment of polycystic ovary syndrome. AbbVie is responsible for all development, marketing and commercialization costs and Neurocrine Biosciences is entitled to a royalty on worldwide sales of ORILISSA, ORIAHNN and any other product containing elagolix.


  • MITSUBISHI TANABE PHARMA

    In March 2015, Neurocrine Biosciences entered into an exclusive collaboration and licensing agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of valbenazine in Japan and other select Asian markets.

    Mitsubishi Tanabe will be responsible for all development, marketing and commercialization costs in their territories and Neurocrine Biosciences will be entitled to a percentage of sales by Mitsubishi Tanabe. Neurocrine Biosciences retains full commercial rights to valbenazine in North America, Europe and other countries outside of Asia.


Annual Meeting & Reports

Information for the 2022 Annual Shareholders Meeting will be available in Q2 2022.

Click below to view our Annual Reports.

*These files are PDFs. To view them you need Adobe Acrobat. If you do not have Acrobat, you may click here to download it.

Image

Ownership

Shareholders
Shareholder Holders Value ($MM) %O/S Shares
Institution 613 9,115.99 99.03 93,729,915
Institution 613 9,115.99 99.03 93,729,915
Institution 613 9,115.99 99.03 93,729,915
Rotation
Shareholder Holders Value ($MM) %O/S Shares
Institution 613 9,115.99 99.03 93,729,915
Institution 613 9,115.99 99.03 93,729,915
Institution 613 9,115.99 99.03 93,729,915

* Insider values reflect direct beneficial ownership. Copyright Refinitiv

Corporate Governance

View the Vermont Prescriber Information:

Notice to Vermont Prescribers. The Vermont “Pharmaceutical Marketer Price Disclosure Law (33 V.S.A. 2005a)”, requires pharmaceutical marketers to disclose to Vermont doctors and other prescribers the prices of drugs they market as well as the prices of other drugs in the same therapeutic class. This information for Neurocrine Biosciences, Inc. products is provided.

The Board of Directors of Neurocrine Biosciences has adopted a Code of Business Conduct and Ethics applicable to employees, directors, consultants and vendors, a link to which can be found above on this page. The Board has also established an ethics hotline for reporting potential violations of this Code.

If you have any questions or concerns, you can contact the Neurocrine Ethics Hotline at 800-688-2908 or NeurocrineEthics.com.

*These files are PDFs. To view them you need Adobe Acrobat. If you do not have Acrobat, you may click here to download it.

Image

Corporate Sustainability

Click below For Neurocrine Biosciences’ Approach To Environment, Social And Governance (ESG) Programs